CompaniesIldong Pharmaceutical

Ildong Pharmaceutical

active

Seoul, Korea

Founded 1941

Website

About

Drugs, Devices

Areas of Focus

Categories

Small Molecule PharmaceuticalWound Healing

Clinical Trials (54)

View all

Total Trials

As Lead Sponsor

As Collaborator

Total Enrollment

14,669

By Phase

PHASE1: 25PHASE3: 14PHASE4: 4NA: 3PHASE2: 1

By Status

COMPLETED: 28UNKNOWN: 22TERMINATED: 3RECRUITING: 1

Clinical Trials Pipeline54 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

Today

NCT01769157

Effects of L-carnitine on Hypothyroidism

Phase: Phase 4

Role: Collaborator

Start: Aug 31, 2012

Completion: Jun 30, 2013

NCT04001400

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Phase: Phase 3

Role: Collaborator

Start: Oct 10, 2012

Completion: May 21, 2014

NCT02088918

A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 31, 2012

Completion: Not specified

NCT02088918

NCT02103686

Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 30, 2012

Completion: Jan 31, 2013

NCT01838967

A Drug Interaction Study of Cilnidipine and Valsartan

Phase: Phase 1

Role: Lead Sponsor

Start: Apr 30, 2013

Completion: Oct 31, 2013

NCT02087540

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2013

Completion: Not specified

NCT02087540

NCT02103647

Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2013

Completion: Jun 30, 2013

NCT02106130

A Drug Interaction Study of Mosapride and Rebamipide

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2013

Completion: Aug 31, 2013

NCT01880502

Pharmacokinetic Study of Belviq in Adult Korean Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Jun 30, 2013

Completion: Oct 31, 2013

NCT01904318

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 31, 2013

Completion: Jan 31, 2014

NCT01937806

Phase 3 and Extensional Study of Besifovir

Phase: Phase 3

Role: Lead Sponsor

Start: Oct 31, 2013

Completion: Jan 31, 2023

NCT01937806

NCT03889145

A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 19, 2013

Completion: Feb 19, 2014

NCT02034292

Safety Study of APD-791 With Aspirin and/or Clopidogrel

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 28, 2014

Completion: Mar 31, 2014

NCT02088008

A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan

Phase: Phase 1

Role: Lead Sponsor

Start: May 31, 2014

Completion: Not specified

NCT02088008

NCT02145104

Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension

Phase: Phase 3

Role: Lead Sponsor

Start: Jun 17, 2014

Completion: Sep 29, 2016

NCT02251847

The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2014

Completion: Not specified

NCT02251847

NCT03761082

Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy

Phase: N/A

Role: Lead Sponsor

Start: Jul 31, 2014

Completion: Apr 30, 2017

NCT03761082

NCT02262143

Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 30, 2014

Completion: Jun 30, 2017

NCT02262143

NCT02300688

Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 31, 2014

Completion: Feb 28, 2015

NCT03741010

Belviq Tablet® Post Marketing Surveillance Protocol

Phase: N/A

Role: Lead Sponsor

Start: Feb 2, 2015

Completion: Feb 1, 2021

NCT03741010

NCT02343250

A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2015

Completion: Not specified

NCT02343250

NCT02419820

Dose-escalation, Repeated and Single Oral Dosing Study

Phase: Phase 1

Role: Lead Sponsor

Start: Mar 31, 2015

Completion: Apr 30, 2016

NCT02738632

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

Phase: Phase 3

Role: Lead Sponsor

Start: May 31, 2015

Completion: Aug 31, 2016

NCT03742544

Post Marketing Surveillance of Telostop TAB (Telmisartan/Rosuvastatin) for Evaluating the Safety and Efficacy

Phase: N/A

Role: Lead Sponsor

Start: Jun 23, 2015

Completion: Oct 30, 2020

NCT03742544

NCT02486497

Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining

Phase: N/A

Role: Collaborator

Start: Jun 30, 2015

Completion: May 31, 2017

NCT02792088

Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues

Phase: Phase 3

Role: Lead Sponsor

Start: Jul 31, 2015

Completion: Feb 29, 2020

NCT02792088

NCT03566316

Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

Phase: Phase 3

Role: Lead Sponsor

Start: Nov 24, 2015

Completion: Jun 16, 2017

NCT02739672

Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Jan 2, 2016

Completion: Apr 6, 2016

NCT02827578

Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia

Phase: Phase 3

Role: Lead Sponsor

Start: Jan 31, 2016

Completion: Dec 31, 2017

NCT02862483

The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 31, 2016

Completion: Mar 31, 2017

NCT03363269

Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease

Phase: Phase 2

Role: Lead Sponsor

Start: Apr 12, 2016

Completion: Apr 17, 2019

NCT03363269

NCT02749994

A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2016

Completion: Feb 28, 2017

NCT02831543

Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients.

Phase: Phase 3

Role: Lead Sponsor

Start: Apr 30, 2016

Completion: Jun 30, 2017

NCT03032315

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 1, 2016

Completion: Dec 27, 2016

NCT03964103

qQ-lab Daily-IBS for Irritable Bowel Syndrome

Phase: N/A

Role: Lead Sponsor

Start: Oct 4, 2016

Completion: Jan 22, 2018

NCT03642340

A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo

Phase: N/A

Role: Lead Sponsor

Start: May 15, 2017

Completion: Aug 15, 2023

NCT03642340

NCT03655288

A Post-marketing Surveillance to Assess Safety and Efficacy of Twotopsplus.

Phase: N/A

Role: Lead Sponsor

Start: Jul 25, 2017

Completion: Nov 30, 2023

NCT03655288

NCT03317743

Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors

Phase: Phase 1

Role: Collaborator

Start: Aug 29, 2017

Completion: Oct 13, 2021

NCT03317743

NCT03604016

Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver

Phase: Phase 4

Role: Lead Sponsor

Start: Sep 23, 2018

Completion: Jul 30, 2020

NCT03648788

A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe

Phase: N/A

Role: Lead Sponsor

Start: Sep 30, 2018

Completion: Aug 31, 2024

NCT03648788

NCT03648801

A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

Phase: N/A

Role: Lead Sponsor

Start: Sep 30, 2018

Completion: Aug 31, 2024

NCT03648801

NCT03885778

A Food Effect Study of Besifovir in Healthy Subjects

Phase: Phase 4

Role: Lead Sponsor

Start: Jan 13, 2019

Completion: Feb 12, 2019

NCT03907228

Study to Evaluate the Use of RHT-3201 in SCORAD Reduction in Young Patients With Atopic Dermatitis

Phase: N/A

Role: Lead Sponsor

Start: Mar 15, 2019

Completion: May 31, 2020

NCT04202536

Switching From Tenofovir Disoproxil Fumarate to Besifovir Dipivoxil Maleate

Phase: Phase 4

Role: Lead Sponsor

Start: May 29, 2019

Completion: Oct 31, 2021

NCT04202536

NCT03937648

Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Aug 1, 2019

Completion: Dec 31, 2019

NCT04249908

Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 13, 2020

Completion: Apr 30, 2021

NCT04185090

To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 29, 2020

Completion: Apr 30, 2020

NCT04218162

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean

Phase: Phase 3

Role: Lead Sponsor

Start: Mar 24, 2020

Completion: Oct 30, 2020

NCT04982705

IDG-16177 for the Evaluation of Its Safety and Pharmacokinetics

Phase: Phase 1

Role: Lead Sponsor

Start: Jul 7, 2021

Completion: Dec 30, 2022

NCT05259020

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Feb 22, 2022

Completion: Mar 30, 2022

NCT05604287

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

Phase: Phase 1

Role: Lead Sponsor

Start: Oct 10, 2022

Completion: Apr 12, 2024

NCT05663879

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers

Phase: Phase 1

Role: Lead Sponsor

Start: Dec 7, 2022

Completion: Jul 31, 2023

NCT06063291

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 20, 2023

Completion: Jul 11, 2024

NCT06635226

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects

Phase: Phase 1

Role: Lead Sponsor

Start: Nov 13, 2024

Completion: Jun 19, 2025

Hover over trial bars to see details

Recent Trials

NCT06635226Lead Sponsor

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ID110521156 in Healthy Adult Subjects

PHASE1Recruiting

36 participants

Started: Nov 13, 2024 · Completed: Jun 19, 2025

NCT06063291Lead Sponsor

Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

PHASE1Completed

36 participants

Started: Nov 20, 2023 · Completed: Jul 11, 2024

NCT05663879Lead Sponsor

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of ID120040002 in Healthy Volunteers

PHASE1Unknown

86 participants

Started: Dec 7, 2022 · Completed: Jul 31, 2023

NCT05604287Lead Sponsor

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

PHASE1Terminated

67 participants

Started: Oct 10, 2022 · Completed: Apr 12, 2024

NCT05259020Lead Sponsor

To Evaluate the Pharmacokinetics and the Safety of ID14009 Compared to Coadministration of ID1805 With ID1803 in Healthy Adult Volunteers

PHASE1Unknown

60 participants

Started: Feb 22, 2022 · Completed: Mar 30, 2022

View all 54 trials →

Locations (1)

Headquarters

Seoul, Korea

Map

Loading map...